ASX:ATX - Benefit of Narmafotinib in kRas-Mutated Cancer Models

Amplia Therapeutics Limited

Clinical Trials

Investor Centre

Investor Fact Sheet Share Price ASX Announcements Reports Top 20 Shareholders Research Reports Shareholder Services Investor FAQs US Shareholders Investor Newsletters

Communication

In the News Presentations Video Updates

About Us

Company Overview Board Team Advisers Values Corporate Directory Corporate Governance

Benefit of Narmafotinib in kRas-Mutated Cancer Models

Your question will be visible to everyone.

Start the conversation

Ask Amplia a question about this announcement.

Share your feedback

Discover